Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Zaijie Jim Wang, PhD
Researcher Professor of Pharmacology
The University of Illinois at Chicago
833 S. Wood St
Room 355, MC 865
Chicago, Illinois, United States
Dr. Wang is a professor of pharmacology and university scholar at the University of Illinois, Chicago. He is associated with various departments and centres of the university such as Department of Biopharmaceutical Sciences, Center for Biomolecular Sciences, Program for Collaborative Research in the Pharmaceutical Sciences, Cancer Center and Sickle Cell Center. A major objective of his laboratory is to understand the mechanisms leading to chronic pain, opioid tolerance and addiction, and opioid-induced hyperalgesia. He is also interested in developing new therapeutic targets as well as novel drugs that can be used for the treatment of pain, where the focus of pain conditions are the pain in sickle cell disease, and chemotherapy-induced pain. Recently professor Zaijie Wang received a MIRA (R35) grant for $4.6M over seven years for a project, entitled “Molecular mechanism and targeting of chronic pain in sickle cell disease”.
Representative Publications:
PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model.
CaMKIIα underlies the spontaneous and evoked pain behaviors in Berkeley sickle cell transgenic mice.
IL1A rs1800587 associates with chronic noncrisis pain in sickle cell disease.
Mechanism-Driven Phase I Translational Study of Trifluoperazine in Adults with Sickle Cell Disease.
Related Content
-
Tamara Nicole New, MDTamara Nicole New, MD works as Assistant...
-
High mortality among children with sickle cell anemia and overt stroke who discontinue blood transfusion after trans...BACKGROUND: Chronic blood transfusion is...
-
Ugochi O. Ogu, MDDr. Ogu currently serves as an Assistant...
-
A survey of sickle cell patients transitioned to adult care from Texas children’s hematology center between Januar...An estimated 93-98% of sickle cell disea...
-
PCORI Board Approves $18 Million for Research on Sickle Cell DiseaseThe Patient-Centered Outcomes Research I...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Sickle Cell Disease: Data Saves Lives“One minute I’d be fine, the next mi...
+myBinder